Press Releases

October 20, 2022
We presented new data during IDWeek 2022 for our novel investigational antibiotic cefepime-taniborbactam, including wo oral presentations showcasing cefepime-taniborbactam and highlighting the safety and efficacy results from our recently completed pivotal Phase 3 complicated urinary tract infection clinical trial, CERTAIN-1.
October 19, 2022
We are excited to present new data at IDWeek 2022, October 19-23, 2022, in Washington, DC for our novel antibiotic cefepime-taniborbactam, including 2 oral presentations showcasing cefepime-taniborbactam and highlighting the safety and efficacy results from our recently completed pivotal Phase 3 complicated urinary tract infection (cUTI) clinical trial, CERTAIN-1.
October 03, 2022
We are honored to be selected by BARBA for Project BioShield. We are confident that cefepime-taniborbactam is extremely well-positioned to help address potential public health emergencies as increasing antibiotic multi-drug resistant infections continue to represent a global threat.

In the News

October 27, 2022
Contagion Live
Venatorx Pharmaceuticals announced successful phase 3 trial results for cefepime-taniborbactam, its investigational antibiotic aimed at treating complicated urinary tract infections.
May 24, 2022
The Hill
What threats do antibiotic-resistant superbugs pose for the future? What is being done to develop new antibiotics and bring life-saving drugs to market? And how can policymakers stimulate innovative drug developments to keep pace with evolving diseases?
April 04, 2022
STAT News
One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.

Upcoming Events

Wednesday, April 05, 2023 - Saturday, April 15, 2023
Thursday, June 15, 2023 - Monday, June 19, 2023